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Abstract
Background: Patients with type 2 diabetes mellitus (DM) have increased risk of endothelial dysfunction and arterial
stiffness. Levels of circulating endothelial progenitor cells (EPCs) are also reduced in hyperglycemic states. However,
the relationships between glycemic control, levels of EPCs and arterial stiffness are unknown.
Methods: We measured circulating EPCs and brachial-ankle pulse wave velocity (baPWV) in 234 patients with type
2 DM and compared them with 121 age- and sex-matched controls.
Results: Patients with DM had significantly lower circulating Log CD34/KDR
+ and Log CD133/KDR
+ EPC counts, and
higher Log baPWV compared with controls (all P < 0.05). Among those 120/234 (51%) of DM patients with satisfactory
glycemic control (defined by Hemoglobin A1c, HbA1c < 6.5%), they had significantly higher circulating Log CD34/KDR
+
and Log CD133/KDR
+ EPC counts, and lower Log baPWV compared with patients with poor glycemic control (all P<
0.05). The circulating levels of Log CD34/KDR
+ EPC (r = -0.46, P < 0.001) and Log CD133/KDR
+ EPC counts (r = -0.45, P<
0.001) were negatively correlated with Log baPWV. Whilst the level of HbA1c positively correlated with Log baPWV (r =
0.20, P < 0.05) and negatively correlated with circulating levels of Log CD34/KDR
+ EPC (r = -0.40, P < 0.001) and Log
CD133/KDR
+ EPC (r = -0.41, P < 0.001). Multivariate analysis revealed that HbA1c, Log CD34/KDR
+ and Log CD133/KDR
+
EPC counts were independent predictors of Log baPWV (P < 0.05).
Conclusions: In patients with type 2 DM, the level of circulating EPCs and arterial stiffness were closely related to
their glycemic control. Furthermore, DM patients with satisfactory glycemic control had higher levels of circulating
EPCs and were associated with lower arterial stiffness.
Background
It is well recognized that patients with type 2 diabetes
mellitus (DM) have accelerated stiffening of the elastic
arteries beyond that explained by normal aging [1]. Such
increase in arterial stiffness, as measured by pulse wave
velocity (PWV) may represent a useful integrated index
of vascular status, and has been identified as an inde-
pendent predictor for cardiovascular related mortality in
patients with DM [2]. In patients with DM, one of the
postulated mechanisms of increased arterial stiffness is
hyperglycemia-induced depletion of endothelial nitric
oxide (NO), subsequently leading to endothelial dys-
function [3]. Dysregulation of the NO system has also
been shown to be responsible for the depletion and dys-
function of endothelial progenitor cells (EPCs) in
patients with type 2 DM [4]. Interestingly, studies also
showed that plasma glucose and hemogloblin A1c
(HbA1c) levels inversely correlates with the bioavailabil-
ity of NO in EPCs [5]. Therefore, we hypothesized that
poor glycemic control in patients with type 2 DM is
associated with depletion of circulating EPC and thus
increased arterial stiffness. The purpose of this study
was to investigate the relationships between glycemic
control with circulating EPCs and arterial stiffness in
patients with type 2 DM. * Correspondence: hftse@hkucc.hku.hk
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Study population
Consecutive patients with type 2 DM, as defined by the
WHO criteria [6] and treated with stable oral hypoglyce-
mic agents and insulin, and cardiovascular medications for
at least 6 months were recruited from the medical outpati-
ent clinic. Patients with poorly controlled DM (HbA1c
≥11%), dilated cardiomyopathy, significant valvular heart
disease, chronic atrial fibrillation, New York Heart Asso-
ciation class III/IV heart failure, a history of prior athero-
thrombotic events (including unstable angina, myocardial
infarction, stroke and peripheral vascular disease) or stable
angina; creatinine level >220 μmol/L, acute infectious dis-
ease, chronic obstructive pulmonary disease, hepatic insuf-
ficiency and connective tissue disease were excluded. As a
result, a total of 234 patients with type 2 DM were eligible
for this study.
The control group was recruited from a local health
exhibition and consisted of 121 age- and sex-matched
healthy subjects with fasting blood glucose level <
6.1mmol/L and no history of diabetes or cardiovascular
diseases. A written informed consent was obtained from
each subject and the study was approved by the local insti-
tutional review board.
Study Design
Cardiovascular risk factors including: tobacco smoking,
hypercholesterolemia, hypertension and family history of
cardiovascular disease diagnosed in first-degree relatives
before 55 years of age were assessed. Baseline demo-
graphic data and cardiovascular medications were
recorded in all subjects [7]. Hypertension was defined as
either resting systolic or diastolic blood pressure >140 or
>90mmHg, at two different clinical visits or the prescrip-
tion of anti-hypertensive medications. Hypercholesterole-
mia was defined as fasting total plasma cholesterol of
≥4.9mmol/L or the prescription of lipid-lowering medica-
tions. Smoking status was recorded as ever-smoker (past
or current) or non-smoker.
Anthropometric measurements including body weight
and waist-hip circumference ratio (WHR) were performed.
Body-mass index (BMI) was calculated as kg/m
2. Systolic
and diastolic blood pressures were measured. Fasting
blood samples were obtained to measure serum levels of
glucose, HbA1c, total cholesterol, triglyceride, low-density
lipoprotein-cholesterol (LDL-C), high-density lipoprotein-
cholesterol (HDL-C), creatinine and number of circulating
EPCs. Glomerular filtration rate (GFR) was calculated
using the Modification of Diet in Renal Disease Study
equation.
Arterial stiffness
Arterial stiffness was measured non-invasively, by a sin-
gle experienced operator, with the VP-2000 System
(Colin Corp., USA) and represented as brachial to ankle
pulse wave velocity (baPWV). Previous studies have vali-
dated that baPWV was closely correlated with aortic
PWV as a measurement of arterial stiffness [8]. Patients
were allowed to rest for 5 minutes and the sites of maxi-
mum arterial pulsation were determined by physical
examination. Sequential recordings of pressure wave-
forms at the brachial and posterior tibial arteries were
made using hand-held manometer probes with simulta-
neous electrocardiogram gating. Measurements were
taken after achieving coherent reproduction of signals
with maximum amplitudes.
Transmission time (TBA) was defined as the time inter-
val between the initial increase in brachial and posterior
tibial waveforms. Transmission distance from the supras-
ternal notch to the brachium (DB)a n da n k l e( D A)w e r e
determined by direct superficial measurement. The value
baPWV was automatically calculated as the transmission
distance divided by the transmission time: baPWV = (DA -
DB)/TBA. After obtaining bilateral baPWV values, the
mean value of the two was used for subsequent analysis.
Intra-observer variability testing revealed an intra-class
correlation coefficient of 0.89 (P < 0.001).
Circulating endothelial progenitor cells
Circulating EPCs were measured by fluorescence-acti-
vated cell analysis of a peripheral blood sample and
defined by the expression of surface markers: CD34/KDR
+ and CD133/KDR
+ [7]. In brief, 100 μlo fp e r i p h e r a l
blood was incubated with a phycoerythrin-conjugated
monoclonal antibody against human KDR (Sigma, St
Louis, Missouri, USA), followed by a fluorescein isothio-
cyanate (FITC)-conjugated CD34 and CD133 antibodies
(Beckman Coulter, Fullerton, California, USA). FITC-
labeled anti-human CD45 antibody was used for differen-
tial gating during flow analysis. FITC-labeled IgG1a
(Beckman Coulter) and phycoerythrin-labeled IgG2b
(Becton Dickinson, Franklin Lakes, New Jersey, USA)
served as the isotypic control for color compensation.
Analysis was performed with an automated fluorescence-
activated cell counter (Elite; Beckman Coulter) in which
1,000,000 events were counted. The percentages of all
the measured components defined as the absolute cell
counts divided by the lymphocyte counts were calculated.
Intra-observer variability testing revealed an intra-class
correlation coefficient of 0.90 (P < 0.001).
Statistical analysis
Data were expressed as mean ± standard deviation for
continuous variables and proportions for categorical
variables. Baseline characteristics were compared
between groups using independent samples t-test or
Fisher’s exact test, as appropriate. Patients with type 2
DM were divided into those with satisfactory glycemic
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control (HbA1c ≥6.5%).
Since the distribution pattern of baPWV and the
number of circulating EPCs were highly skewed, these
variables were log-transformed to normalize their distri-
bution before analysis. Correlation coefficients were cal-
culated to assess the association between the circulating
EPCs and baPWV. Stepwise backward linear regression
analysis was used to identify independent predictors for
circulating EPCs and baPWV. Only parameters with P<
0.1 in uni-variate analysis were subsequently entered
into a multi-variate model. All statistical analyses were
performed using the statistical package SPSS for Win-
dows (Version 15.0, SPSS, Chicago, USA). A P value <
0.05 was considered as statistically significant.
Results
Clinical characteristics
As shown in Table 1, there were no significant differ-
ences in age or sex between patients with type 2 DM and
controls (all P>0.05). Patients with type 2 DM had signifi-
cantly higher prevalence of hypertension, hypercholester-
olemia and smokers, greater BMI and WHR, and more
likely to be prescribed with anti-hypertensive medica-
tions, statins and aspirin (Table 1, P<0 . 0 1 ). Further-
more, the serum fasting glucose, HbA1c, triglyceride and
creatinine levels were higher and the GFR was lower in
DM patients as compared with controls (Table 1, P<
0.01). In contrast, DM patients had significantly lower
serum total cholesterol and LDL-C than controls which
were likely due to an increased use of statins in DM
patients.
Among those patients with DM, 120/234 (51%) of them
had satisfactory glycemic control with HbA1c < 6.5%. As
expected, DM patients with satisfactory glycemic control
had a significantly lower serum fasting glucose and HbA1c
levels compared with those with poor glycemic control
(Table 2, P < 0.01). Furthermore, DM patients with satis-
factory glycemic control had a lower prevalence of hyper-
tension, hyperlipidemia, smoking history and were less
frequently prescribed with insulin than those with poor
glycemic control (Table 2, P < 0.05). However, there were
no significant differences in the serum lipid profile, GFR
and use of cardiovascular medications between the two
groups (Table 2, P>0.05).
Circulating endothelial progenitor cells and arterial
stiffness
Compared with controls, patients with type 2 DM had
significantly lower circulating Log CD34/KDR
+ EPCs
(0.96 ± 0.31 10
-3/ml vs. 1.23 ± 0.36 10
-3/ml, P < 0.01) and
Log CD133/KDR
+ EPCs (0.70 ± 0.26 10
-3/ml vs. 1.13 ±
0.38 10
-3/ml, P < 0.01). Among patients with DM, those
with satisfactory glycemic control had significantly higher
levels of circulating Log CD34/KDR
+ EPCs (1.05 ± 0.27
10
-3/ml vs. 0.88 ± 0.32 10
-3/ml, P < 0.01)a n dL o g
CD133/KDR
+ EPCs (0.78 ± 0.28 10
-3/ml vs. 0.61 ± 0.21
10
-3/ml, P < 0.01) than those with poor glycemic control.
Arterial stiffness as measured by Log baPWV, was sig-
nificantly greater in patients with type 2 DM as com-
pared with controls (3.24 ± 0.08 cm/s vs. 3.18 ±
0.09 cm/s, P<0 . 0 1 ). Among patients with DM, those
with satisfactory glycemic control had significantly lower
Log baPWV than those with poor glycemic control
(3.23 ± 0.08 cm/s vs. 3.27 ± 0.09 cm/s, P < 0.05).
The circulating levels of Log CD34/KDR+ EPCs (r =
-0.46, P < 0.001, Figure 1) and Log CD133/KDR+ EPCs
(r = -0.45, P < 0.001, Figure 2) were negatively corre-
lated with Log baPWV. Whilst the level of HbA1c posi-
tively correlated with Log baPWV (r = 0.20, P < 0.05)
and negatively correlated with circulating levels of Log
Table 1 Clinical characteristics of patients with DM and
Controls
DM patients
n = 234
Controls
n = 121
P-value
Age, years 56.5 ± 7.6 56.5 ± 8.4 0.99
Males, n (%) 119 (51) 59 (49) 0.74
Hypertension, n (%) 96 (41) 18 (15) < 0.01
Hypercholesterolemia, n (%) 114 (49) 24 (20) < 0.01
Ever-smokers, n (%) 72 (31) 7 (6) < 0.01
Duration of DM, yrs 10.0 ± 8.0 -
Body-mass index, kg/m
2 25.1 ± 4.7 21.5 ± 3.2 < 0.01
Waist-hip circumference ratio 0.9 ± 0.1 0.8 ± 0.1 < 0.01
Body weight, kg 64.6 ± 10.6 56.4 ± 9.1 < 0.01
Systolic blood pressure, mmHg 144.2 ± 21.2 118.8 ± 22.9 < 0.01
Diastolic blood pressure, mmHg 79.6 ± 8.8 72.3 ± 8.2 < 0.01
Fasting blood glucose, mmol/L 7.2 ± 2.2 4.9 ± 0.5 < 0.01
HbA1c, % 7.7 ± 1.5 5.8 ± 0.3 < 0.01
Triglyceride, mmol/L 1.6 ± 1.2 1.3 ± 0.9 < 0.01
Total cholesterol, mmol/L 4.6 ± 0.9 5.1 ± 0.8 < 0.01
LDL-C, mmol/L 2.6 ± 0.8 2.9 ± 0.7 < 0.01
HDL-C, mmol/L 1.3 ± 0.4 1.6 ± 0.4 < 0.01
Creatinine, μmol/L 84.6 ± 27.2 71.0 ± 16.6 < 0.01
GFR, ml/min/1.73m
2 55.4 ± 15.3 60.0 ± 13.7 < 0.01
Beta-blocker, n (%) 106 (45%) 10 (8%) < 0.01
Calcium channel blocker, n (%) 77 (33%) 3 (2%) < 0.01
ACEI/ARB, n (%) 122 (52%) 6 (5%) < 0.01
Aspirin, n (%) 103 (44%) 9 (7%) < 0.01
Statin, n (%) 119 (51%) 9 (7%) < 0.01
Insulin, n (%) 35 (15%) 0 (0%) < 0.01
Log CD34/KDR
+ EPCs, 10
-3/ml 0.96 ± 0.31 1.23 ± 0.36 < 0.01
Log CD133/KDR
+ EPCs, 10
-3/ml 0.70 ± 0.26 1.13 ± 0.38 < 0.01
Log baPWV, cm/s 3.24 ± 0.08 3.18 ± 0.09 < 0.01
Abbreviations: T2DM = Type 2 diabetes mellitus; HbA1c = hemoglobin A1c;
LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein
cholesterol; GFR = glomerular filtration rate; ACEI = angiotensin converting
enzyme inhibitor; ARB = angiotensin receptor blocker; EPC = endothelial
progenitor cell; baPWV = brachial-ankle pulse wave velocity
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Page 3 of 7Table 2 Clinical characteristics of DM patients with satisfactory (HbA1c < 6.5%) or poor (HbA1c≥6.5%) glycemic
control
HbA1c < 6.5%
(n = 120)
HbA1c≥6.5%
(n = 114)
P-value
Age, years 56.5 ± 8.5 56.8 ± 8.4 0.81
Males, n (%) 62 (52) 57 (50) 0.35
Hypertension, n (%) 40 (33) 58 (51) < 0.05
Hypercholesterolemia, n (%) 52 (43) 62 (54) < 0.01
Ever-smokers, n (%) 29 (24) 43 (38) < 0.01
Duration of DM, yrs 9.7 ± 7.0 10.3 ± 8.6 0.37
Body-mass index, kg/m
2 25.4 ± 4.3 24.9 ± 5.2 0.48
Waist-hip circumference ratio 0.9 ± 0.1 0.9 ± 0.1 0.38
Body weight, kg 64.2 ± 11.7 65.6 ± 10.3 0.52
Systolic blood pressure, mmHg 145.2 ± 23.2 143.1 ± 18.5 0.45
Diastolic blood pressure, mmHg 77.9 ± 7.8 80.4 ± 9.5 0.08
Fasting blood glucose, mmol/L 5.7 ± 1.2 8.5 ± 2.3 < 0.01
HbA1c, % 6.1 ± 0.5 8.8 ± 1.3 < 0.01
Triglyceride, mmol/L 1.5 ± 1.1 1.7 ± 1.3 0.18
Total cholesterol, mmol/L 4.6 ± 0.9 4.5 ± 0.9 0.27
LDL-C, mmol/L 2.6 ± 0.8 2.5 ± 0.7 0.21
HDL-C, mmol/L 1.3 ± 0.4 1.2 ± 0.4 0.06
Creatinine, μmol/L 82.8 ± 21.6 85.7 ± 31.0 0.42
GFR, ml/min/1.73m
2 56.4 ± 12.1 55.0 ± 17.2 0.39
Beta-blocker, n (%) 56 (47) 50 (44) 0.34
Calcium channel blocker, n (%) 35 (29) 42 (37) 0.08
ACEI/ARB, n (%) 57 (48) 65 (57) 0.06
Aspirin, n (%) 48 (40) 55 (48) 0.13
Statin, n (%) 57 (48) 62 (54) 0.11
Insulin, n(%) 9 (8) 26 (23) < 0.01
Log CD34/KDR
+ EPCs, 10
-3/ml 1.05 ± 0.27 0.88 ± 0.32 < 0.01
Log CD133/KDR
+ EPCs, 10
-3/ml 0.78 ± 0.28 0.61 ± 0.21 < 0.01
Log baPWV, cm/s 3.23 ± 0.08 3.27 ± 0.09 < 0.05
Abbreviations as in Table 1
Figure 1 Relationship between levels of circulating Log CD34/
KDR
+ EPCs with Log baPWV in patients with DM.
Figure 2 Relationship between levels of circulating Log CD133/
KDR
+ EPCs with Log baPWV in patients with DM.
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Page 4 of 7CD34/KDR+ EPCs (r = -0.40, P < 0.001,F i g u r e3 )a n d
Log CD133/KDR+ EPCs (r = -0.41, P < 0.001, Figure 4).
Multivariate regression analysis revealed that in
patients with diabetes, HbA1c, diabetes duration, Log
CD34/KDR
+ EPCs and Log CD133/KDR
+ EPCs were
independent predictors of Log baPWV (Table 3).
Discussion
Our results demonstrate a close inter-relationship
between glycemic control, circulating EPCs and arterial
stiffness in patients with type 2 DM. Patients with type 2
DM had a lower level of circulating EPCs and increased
arterial stiffness compared with normal controls.
Amongst those with diabetes, a poor glycemic control
correlated with a lower number of EPCs as well as
increased arterial stiffness, whilst better glycemic control
correlated with a relatively greater number of EPCs as
well as a lesser degree of arterial stiffness. Furthermore,
after adjusting for other cardiovascular risk factors and
medications, glycemic control and EPC counts were
identified as independent risk predictors for arterial
stiffness.
The mechanisms by which hyperglycemia leads to an
increase in arterial stiffness remain unclear but is likely
related to an imbalance between the protective versus
detrimental pathways. Vascular endothelial cells secrete
large amounts of chemical mediators and biologically
active substances that actively regulate vascular tone and
permeability [9]. Among those protective substances
secreted, NO is one of the main factor which has vasodi-
latory, anti-platelet, anti-inflammatory and anti-oxidant
properties for maintenance of endothelial function [10].
However, in the presence of chronic hyperglycemia,
polyol, protein kinase C and pentose phosphate pathways
are enhanced. These pathways are detrimental to the vas-
cular endothelium and results in an increased oxidative
stress and accelerated endothelial cell apoptosis [11,12].
Furthermore, the availability and biological activity of
NO are also reduced in hyperglycemic states, resulting in
worsening endothelial dysfunction [13-16]. In addition,
hyperglycemia induces vascular smooth muscle cell pro-
liferation as well as promotes their conversion from the
contractile phenotype to the synthentic phenotype, thus
promoting the development of arterial stiffness [17].
On the other hand, circulating EPCs may play an
important role in repairing damaged vascular endothe-
lium [18]. Prior studies have shown that the number of
circulating EPCs was positively correlated to endothelial
function [19]. However, in hyperglycemic states, EPCs
exhibit impaired proliferation, adhesion, and incorpora-
tion into vascular structures [20]. An impairment of vas-
cular NO system has also been shown to result in the
dysfunction and depletion of EPCs [4]. Indeed, the levels
of circulating EPCs were reduced in patients with type 2
DM as compared with normal subjects, and have been
shown to have a significant inverse correlation with
serum glucose and HbA1c levels [21]. EPCs have also
been found to be reduced in pre-diabetic states
(impaired fasting glucose and impaired glucose toler-
ance) with further significantr e d u c t i o n si nn u m b e ra t
the clinical onset of diabetes and after ~20 years of dis-
ease [22]. Moreover, recent interesting studies noted
reduced numbers and functions of EPCs in subjects who
are predisposed to having DM (e.g. polycystic ovarian
syndrome), indicating that reduced EPCs may even be a
risk factor of DM [23].
Consistent with previous studies [24,25], the present
study confirmed that patients with DM have a blunted
Figure 3 Relationship between levels of circulating Log CD34/
KDR
+ EPCs and HbA1c in patients with DM.
Figure 4 Relationship between levels of circulating Log CD133/
KDR
+ EPCs and HbA1c in patients with DM.
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Page 5 of 7endothelium regenerating capacity as reflected by a
decrease in number of circulating EPCs and was asso-
ciated with large artery atherosclerosis as measured by
PWV. Importantly, our results further demonstrated
that the degree of hyperglycemia control in those
patients with type 2 DM was closely related to the levels
of circulating EPCs as well as the arterial stiffness. In
this study, DM patients who could achieve satisfactory
hyperglycemia had significantly higher circulating level
of EPCs and lower arterial stiffness. This might be one
of the mechanisms in which satisfactory glycemic con-
trol in type 2 DM patients (HbA1c < 6.5%) had reduced
cardiovascular events [26]. On the other hand, recent
studies have also shown that an over vigorous lowering
of HbA1c to < 6.0% has been associated with increased
all-cause mortality [27]. The mechanism of such obser-
vations has yet to be determined but is less likely to be
related to a change in PWV and EPC number according
to our findings.
This study has several limitations. First, this was only a
modest size cross-sectional study of approximately 350
subjects and the result needs further confirmation in
other cohorts. Second, the causal relationship between
reduced circulating EPC and arterial stiffness could not
be confirmed. Whether improved glycemic control in
DM patients can increase circulating EPCs and decrease
arterial stiffness needs to be confirmed in future prospec-
tive studies. Third, the effect of hyperinsulinemia and
insulin resistance on circulating EPCs counts, endothelial
function and arterial stiffness were not assessed in the
present study. Forth, in addition to the number of circu-
lating EPCs, the function of EPCs might also play an
important role in vascular repair. Unfortunately, the
function of EPCs was not measured in this study.
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